Digital healthcare specialist SCL Science announced on June 27 that key executives, including CEO Baek Seyeon, have purchased company shares on the open market.
SCL Science CEO Baek Seyeon acquired a total of 9,500 company shares on the open market between June 20 and June 25. The total purchase amount by Baek and other executives was approximately 400 million KRW.
Baek stated, "This purchase of company shares is based on a strong belief in the company's future growth potential and the enhancement of shareholder value," adding, "Executives have also voluntarily participated in the purchase of company shares to practice responsible management."
She further emphasized, "We will continue to strengthen trust with the market by prioritizing shareholder value in our management going forward."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
